Results 131 to 140 of about 19,188,679 (307)

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Descriptive characteristics at initiation of second-line TB treatment of RR-TB patients.

, 2016
Descriptive characteristics at initiation of second-line TB treatment of RR-TB patients.
Ian Sanne (170641), Denise Evans (288201), Sydney Rosen (213204), Kamban Hirasen (3331569), Kathryn Schnippel (320845), Erika Mohr (3331566), Rebecca Berhanu (442834)   +6 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study

Future Science OA
Background Pancreatic cancer (PC) is often diagnosed at advanced stages, limiting surgical options. There is no standardized treatment for second-line or beyond therapies, necessitating alternative treatments. This study evaluates the efficacy and safety
Zhiyong Li, Zhiming Wang, Hexia Gan, Feng Shen, Lisha Cheng, Xiuping Zhang   +5 more
doaj   +1 more source

The unexpected success of NRTIs in second-line treatment [PDF]

The Lancet Infectious Diseases, 2018
Andrew M, Hill, Francois, Venter
openaire   +2 more sources

A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment [7]

, 1999
A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment ...
Ali A., Menegatti M., Landi F., Miglioli M., Ricci C., Gatta L., Vaira D., Acciardi C.   +7 more
core   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Multidrug resistant tuberculosis: Role of previous treatment with second line therapy on treatment outcome

Lung India, 2007
Setting: The tuberculosis referral center of a tertiary care hospital. Objective: To determine human immunodeficiency virus (HIV) seropositivity, diabetes mellitus (DM), treatment outcome, cost, and adverse drug reaction in patients with multi-drug ...
Singh R, Gothi D, Joshi J
doaj  

Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study

Gut and Liver
Background/Aims : Optimal second-line (2L) and third-line (3L) systemic therapies after first-line (1L) atezolizumab plus bevacizumab (AtezoBev) for advanced hepatocellular carcinoma (HCC) remain undefined.
Yuri Cho, Jeong-Hoon Lee, Baek-Yeol Ryoo, Ho Yeong Lim, Dong Eun Lee, Bo Hyun Kim, Joong-Won Park   +6 more
doaj   +1 more source